Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      Suven Life Sciences gets Product Patents in Israel and Japan

      Suven Life Sciences gets Product Patents in Israel and Japan

      Medical Dialogues Bureau8 Nov 2018 9:25 AM IST
      HYDERABAD: Suven Life Sciences Ltd has recently announced the grant of one product patent from Israel and one product patent from Japan corresponding...
      Foamixs treatment for common skin condition meets late-stage trial goals

      Foamix's treatment for common skin condition meets late-stage trial goals

      Medical Dialogues Bureau8 Nov 2018 9:00 AM IST
      Foamix hopes to be the first to bring a foam formation of minocycline, which is typically available in oral dosage forms, to the market.New Delhi:...
      Unichem acquires 20 percent stake in Optimus group for Rs 120 Crore

      Unichem acquires 20 percent stake in Optimus group for Rs 120 Crore

      Medical Dialogues Bureau7 Nov 2018 10:45 AM IST
      Mumbai: Pharma firm, Unichem Laboratories has recently announced that the company has entered into an agreement to acquire a 20 per cent equity stake...
      Cipla Q2 consolidated net profit declines by 15.64 percent

      Cipla Q2 consolidated net profit declines by 15.64 percent

      Medical Dialogues Bureau7 Nov 2018 9:45 AM IST
      Mumbai: Pharma major, Cipla Ltd has posted a decline of 15. 64 per cent in its consolidated net profit for the quarter ended September 30, 2018, at Rs...
      FDA approves Pfizer

      FDA approves Pfizer's Lorbrena treatment for certain lung cancer patients

      Medical Dialogues Bureau7 Nov 2018 9:40 AM IST
      Lorbrena, known chemically as lorlatinib, received an accelerated approval, Pfizer said. Its continued approval may depend on verification of clinical...
      Natco Pharma Q2 Profit up 35 percent to Rs 583 Crore

      Natco Pharma Q2 Profit up 35 percent to Rs 583 Crore

      Medical Dialogues Bureau7 Nov 2018 9:15 AM IST
      Hyderabad: Natco Pharma Limited has recorded consolidated total revenue of INR 583.50 Crore for the second quarter ended on 30th September 2018, as...
      Sanofi and Regenerons Dupixent gets more positive feedback from U.S.FDA

      Sanofi and Regeneron's Dupixent gets more positive feedback from U.S.FDA

      Medical Dialogues Bureau7 Nov 2018 9:05 AM IST
      PARIS: The U.S. Food & Drug Administration (FDA) regulator has given more positive feedback on the Dupixent eczema treatment being developed by...
      Lupin gets FDA approval for Doxercalciferol Injection

      Lupin gets FDA approval for Doxercalciferol Injection

      Medical Dialogues Bureau6 Nov 2018 1:03 PM IST
      New Delhi: Pharma major Lupin announced that it has received approval for its Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials from...
      Nephroplus Announces Acquires of DaVita Care India

      Nephroplus Announces Acquires of DaVita Care India

      Medical Dialogues Bureau6 Nov 2018 11:00 AM IST
      Banglore: NephroPlus, India’s largest dialysis care network and a trailblazer in redefining dialysis care in India announced the acquisition of DaVita...
      Faulty Implant: J&J launches IPAP Reimbursement Programme

      Faulty Implant: J&J launches IPAP Reimbursement Programme

      Medical Dialogues Bureau6 Nov 2018 10:15 AM IST
      Johnson & Johnson Private Limited has launched the (ASR) Articular Surface Replacement) India Patient Assistance Program (IPAP) - a unique program...
      Bliss GVS Pharma Q2 profit up 22 Percent to Rs 41.45 crore

      Bliss GVS Pharma Q2 profit up 22 Percent to Rs 41.45 crore

      Medical Dialogues Bureau6 Nov 2018 9:21 AM IST
      NEW Delhi: Bliss GVS Pharma on has reported a 22 per cent increase in consolidated profit to Rs 41.45 crore in the second quarter ended September 30,...
      Roche

      Roche's Schwan says new drugs will replace lost sales - NZZ am Sonntag

      Medical Dialogues Bureau6 Nov 2018 9:05 AM IST
      New Delhi: Roche Cheif Executive Severin Schwan has announced that new drugs the pharma company is developing will replace the roughly 10 billion...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok